Close Menu

NEW YORK – Canbridge Pharmaceuticals said on Thursday that it has received approval from China's National Medical Products Administration to market neratinib (Puma Biotechnology's Nerlynx) as an extended adjuvant treatment of patients with early-stage, HER2-positive breast cancer after treatment with trastuzumab (Genentech's Herceptin).

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.